多发性骨髓瘤患者CRP、LDH及β<sub>2</sub>-MG水平与预后的相关性

doi:10.3969/j.issn.1671-7171.2025.02.024

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1252 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To explore the relationship of prognosis with C-reactive protein (CRP), lactate dehydrogenase (LDH), and β₂-microglobulin (β₂-MG) levels in multiple myeloma (MM) patients.【Methods】A retrospective analysis was conducted on the clinical data of 96 MM patients, including age, gender, International Staging System (ISS) stage, immunoglobulin subtype, comorbidities, coagulation markers, lipid profiles, homocysteine (Hcy) levels, and CRP, LDH, and β₂-MG levels. Factors influencing prognosis were analyzed, and Spearman's correlation test was used to analyze the correlation of prognosis with levels of Hcy, CRP, LDH and β₂-MG.【Results】Among the 96 patients, 79 (82.29%) were alive and were categorized into the survival group, while 17 (17.71%) died and were categorized into the death group. The proportion of ISS stage Ⅱ and Ⅲ, as well as CRP, LDH, β₂-MG, and Hcy levels in the death group, were significantly higher than those in the survival group (P<0.05). CRP, LDH, β₂-MG, and Hcy were found to be significant prognostic factors for MM (P<0.05). Spearman's test showed that Hcy, CRP, LDH, and β₂-MG levels were positively correlated with prognosis (P<0.05).【Conclusion】As the levels of Hcy, CRP, LDH, and β₂-MG increase, the severity of the disease worsens, and the risk of poor prognosis in MM patients rises.

Key words： Multiple Myeloma C-Reactive Protein L-Lactate Dehydrogenase beta 2-Microglobulin Prognosis

Received: 12 January 2023

PACS:

R733.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GUO Xiaodan
	YI Shanyong
	LI Yanyan
	et al

Cite this article:

GUO Xiaodan,YI Shanyong,LI Yanyan, et al. Correlation of CRP, LDH, and β₂-MG Levels with Prognosis in Multiple Myeloma Patients[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(2): 258-260.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.02.024 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I2/258

[1] 陈文明. 多发性骨髓瘤诊治进展[J].临床内科杂志,2021,38(12):793-796.
[2] VICTOR M, EVGENIV H, GERGANA T, et al. Serum hepcidin levels in multiple myeloma[J].Clin Lab,2017,63(7):1273-1277.
[3] 林泽宇,陈文明. 多发性骨髓瘤治疗进展[J].白血病?淋巴瘤,2020,29(3):132-135.
[4] 马柯娃,孙超,李建勇,等. 多发性骨髓瘤预后因素的研究进展[J].中国实验血液学杂志,2021,29(4):1346-1350.
[5] 中国医师协会血液科医师分会,中华医学会血液学分会,中国多发性骨髓瘤工作组. 中国多发性骨髓瘤诊治指南(2011年修订)[J].中华内科杂志,2011,50(10):892-896.
[6] AILAWADHI S, SHER T, PATEL M, et al. International staging system (ISS) is superior to durie-salmon (DS) staging in predicting overall mortality in multiple myeloma (MM)[J].Blood,2008, 112(11):2745.
[7] GUGLIELMELLI T, GIUGLIANO E,BRUNETTO V,et al.mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein[J].Oncoscience,2015, 2(4):382-394.
[8] 程灵灵,魏晓晶,庄婧,等. miR-21与多发性骨髓瘤患者预后的关系及其对化疗耐药的影响和机制[J].山东医药,2020,60(2):14-17.
[9] 高泽莉,王文辉,汪宏云,等. 早期死亡的多发性骨髓瘤患者预后不良因素分析[J].检验医学与临床,2010,7(10):929-930.
[10] SHEN X J, YE Y, QI J, et al. Identification of a novel microRNA, miR-4449, as a potential blood based marker in multiple myeloma[J].Clin Chem Lab Med,2017,55(5):748-754.
[11] 韩少玲,吴亚兵,张家友,等. 多发性骨髓瘤患者血清β₂-MG、CRP和IL-6水平与临床分期的关系[J].河北医药,2021,43(3):353-356.
[12] 陈敏,郭永华,欧阳家乐,等. 多发性骨髓瘤患者血清sFLC、LDH及β₂-MG水平及其与预后的关系[J].国际检验医学杂志,2020,41(10):1183-1186.
[13] 韩少玲,吴亚兵,张家友,等. 血清LDH和 β₂-MG水平与多发性骨髓瘤患者预后的相关性[J].实用癌症杂志,2020,35(11):1817-1825.
[14] 王丽,赵艳莉,金瑄,等. 多发性骨髓瘤患者的血清β₂-MG、TNF-α、IL-6水平及其临床意义[J].海南医学,2020,31(12):1527-1529.
[15] 伏媛,魏小芳,冯友繁,等. 血清同型半胱氨酸水平对初诊多发性骨髓瘤患者预后的影响及相关因素分析[J].中国实验血液学杂志,2021,29(2):530-534.